Emergent Biosolutions (EBS) Gets a Buy Rating from Chardan Capital

By Carrie Williams

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Emergent Biosolutions (EBSResearch Report), with a price target of $71.00. The company’s shares closed last Monday at $58.40.

According to TipRanks.com, Nakae ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.5% and a 37.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Research, Arbutus Biopharma, and Alnylam Pharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Emergent Biosolutions with a $67.80 average price target.

See today’s analyst top recommended stocks >>

Based on Emergent Biosolutions’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.5 million. In comparison, last year the company had a net profit of $20.95 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats.